"/td></tr><tr><td align=\\\"center\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     80 mg single-dose</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">Carton of 1</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">0002-7724-11</td></tr><tr><td align=\\\"center\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     40 mg single-dose</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">Carton of 1</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">0002-8905-11</td></tr><tr class=\\\"Last\\\"><td align=\\\"center\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     20 mg single-dose</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">Carton of 1</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">0002-8900-11</td></tr></tbody></table></section>\",\n            \"useInSpecificPopulations\": \"<section class=\\\"Section\\\" data-sectioncode=\\\"43684-0\\\"><a name=\\\"s43\\\"></a><a name=\\\"section-7\\\"></a><p></p><h1>8 USE IN SPECIFIC POPULATIONS</h1><div class=\\\"Section\\\" data-sectioncode=\\\"42228-7\\\"><a name=\\\"s44\\\"></a><a name=\\\"section-7.1\\\"></a><p></p><h2>8.1 Pregnancy</h2><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s45\\\"></a><a name=\\\"section-7.1.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Pregnancy Exposure Registry</span></p><p>There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to TALTZ during pregnancy. Pregnant women exposed to TALTZ are encouraged to enroll in the TALTZ Pregnancy Registry by calling 1-800-284-1695. Contact information for the registry is also available on http://www.pregnancyregistry.lilly.com.</p><p><span class=\\\"Underline\\\">Risk Summary</span></p><p>Available data from the published literature and the pharmacovigilance database with TALTZ use in pregnant women are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes.           </p><p>Human IgG is known to cross the placental barrier; therefore, TALTZ may be transmitted from the mother to the developing fetus. An embryofetal development study conducted in pregnant monkeys during organogenesis at doses up to 19 times the maximum recommended human dose (MRHD) revealed no evidence of harm to the developing fetus. When dosing was continued until parturition, neonatal deaths were observed at 1.9 times the MRHD <span class=\\\"Italics\\\">[see Data]</span>. The clinical significance of these nonclinical findings is unknown.</p><p>The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s46\\\"></a><a name=\\\"section-7.1.2\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Data</span></p><p><span class=\\\"Italics\\\">Animal Data</span></p><p>An embryofetal development study was conducted in cynomolgus monkeys administered ixekizumab. No malformations or embryofetal toxicity were observed in fetuses from pregnant monkeys administered ixekizumab weekly by subcutaneous injection during organogenesis to near parturition at doses up to 19 times the MRHD (on a mg/kg basis of 50 mg/kg/week). Ixekizumab crossed the placenta in monkeys.</p><p>In a pre- and post-natal development toxicity study, pregnant cynomolgus monkeys were administered weekly subcutaneous doses of ixekizumab up to 19 times the MRHD from the beginning of organogenesis to parturition. Neonatal deaths occurred in the offspring of two monkeys administered ixekizumab at 1.9 times the MRHD (on a mg/kg basis of 5 mg/kg/week) and two monkeys administered ixekizumab at 19 times the MRHD (on a mg/kg basis of 50 mg/kg/week). These neonatal deaths were attributed to early delivery, trauma, or congenital defect. The clinical significance of these findings is unknown. No ixekizumab-related effects on functional or immunological development were observed in the surviving infants from birth through 6 months of age.</p></div></div><div class=\\\"Section\\\" data-sectioncode=\\\"77290-5\\\"><a name=\\\"s48\\\"></a><a name=\\\"section-7.2\\\"></a><p></p><h2>8.2 Lactation</h2><p class=\\\"First\\\"><span class=\\\"Underline\\\">Risk Summary</span></p><p>There are no available data on the presence of ixekizumab in human milk, the effects on the breastfed infant, or the effects on milk production. Ixekizumab was detected in the milk of lactating cynomolgus monkeys. When a drug is present in animal milk, it is likely that the drug will be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for TALTZ and any potential adverse effects on the breastfed infant from TALTZ or from the underlying maternal condition.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"34081-0\\\"><a name=\\\"s50\\\"></a><a name=\\\"section-7.3\\\"></a><p></p><h2>8.4 Pediatric Use</h2><p class=\\\"First\\\">The safety and effectiveness of TALTZ have been established in pediatric subjects aged 6 years to less than 18 years with moderate-to-severe plaque psoriasis. The safety and effectiveness of TALTZ in other pediatric indications and for pediatric subjects less than 6 years of age have not been established.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"34082-8\\\"><a name=\\\"s51\\\"></a><a name=\\\"section-7.4\\\"></a><p></p><h2>8.5 Geriatric Use</h2><p class=\\\"First\\\">Of the 4204 adult psoriasis subjects exposed to TALTZ, a total of 301 were 65 years or older, and 36 subjects were 75 years or older. Although no differences in safety or efficacy were observed between older and younger subjects, the number of subjects aged 65 and over is not sufficient to determine whether they respond differently from younger subjects <span class=\\\"Italics\\\">[see Clinical Pharmacology (<a href=\\\"#s57\\\">12.3</a>)]</span>.</p></div></section>\",\n            \"description\": \"<section class=\\\"Section\\\" data-sectioncode=\\\"34089-3\\\"><a name=\\\"s53\\\"></a><a name=\\\"section-8\\\"></a><p></p><h1>11 DESCRIPTION</h1><p class=\\\"First\\\">Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) with neutralizing activity against IL-17A. Ixekizumab is produced by recombinant DNA technology in a recombinant mammalian cell line and purified using standard technology for bioprocessing. Ixekizumab is comprised of two identical light chain polypeptides of 219 amino acids each and two identical heavy chain polypeptides of 445 amino acids each and has a molecular weight of 146,158 Daltons for the protein backbone of the molecule.</p><p>TALTZ injection is a sterile, preservative free, clear and colorless to slightly yellow solution, for subcutaneous use available as 80 mg of ixekizumab in a 1 mL single-dose prefilled autoinjector or a single-dose prefilled syringe, 40 mg of ixekizumab in a 0.5 mL single-dose prefilled syringe, or 20 mg of ixekizumab in a 0.25 mL single-dose prefilled syringe. The prefilled autoinjector and prefilled syringe each contain a 1 mL glass syringe with a fixed 27 gauge ½ inch needle. The TALTZ 80 mg prefilled autoinjector and prefilled syringe are manufactured to deliver 80 mg of ixekizumab. The TALTZ 40 mg prefilled syringe is manufactured to deliver 40 mg of ixekizumab. The TALTZ 20 mg prefilled syringe is manufactured to deliver 20 mg of ixekizumab.</p><p>Each TALTZ 80 mg/mL single-dose autoinjector or TALTZ 80 mg/mL single-dose prefilled syringe is composed of ixekizumab (80 mg); Polysorbate 80, USP (0.3 mg); Sucrose, USP (80 mg); and Water for Injection, USP. Sodium Hydroxide, USP-NF, may have been added to adjust pH. The TALTZ solution has a pH of 5.2 –  6.2.</p><p>Each TALTZ 40 mg/0.5 mL single-dose prefilled syringe is composed of ixekizumab (40 mg); Polysorbate 80, USP (0.15 mg); Sucrose, USP (40 mg); and Water for Injection, USP. Sodium Hydroxide, USP-NF, may have been added to adjust pH. The TALTZ solution has a pH of 5.2 –  6.2.</p><p>Each TALTZ 20 mg/0.25 mL single-dose prefilled syringe is composed of ixekizumab (20 mg); Polysorbate 80, USP (0.08 mg); Sucrose, USP (20 mg); and Water for Injection, USP. Sodium Hydroxide, USP-NF, may have been added to adjust pH. The TALTZ solution has a pH of 5.2 –  6.2.</p></section>\",\n            \"nonclinicalToxicology\": \"<section class=\\\"Section\\\" data-sectioncode=\\\"43680-8\\\"><a name=\\\"s66\\\"></a><a name=\\\"section-10\\\"></a><p></p><h1>13 NONCLINICAL TOXICOLOGY</h1><div class=\\\"Section\\\" data-sectioncode=\\\"34083-6\\\"><a name=\\\"s67\\\"></a><a name=\\\"section-10.1\\\"></a><p></p><h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2><p class=\\\"First\\\">Animal studies have not been conducted to evaluate the carcinogenic or mutagenic potential of TALTZ. Moreover published literature is mixed on potential effects on malignancy risk due to the inhibition of IL-17A activity, the pharmacological action of TALTZ. Some published literature suggests that IL-17A directly promotes cancer cell invasion, suggesting a potential beneficial effect by TALTZ, whereas other reports indicate IL-17A promotes T-cell mediated tumor rejection, suggesting a potential adverse effect by TALTZ. However, neutralization of IL-17A with TALTZ has not been studied in these models. Depletion of IL-17A with a neutralizing antibody inhibited tumor development in mice, suggesting a potential beneficial effect by TALTZ. The relevance of experimental findings in mouse models for malignancy risk in humans is unknown.</p><p>No effects on fertility parameters such as reproductive organs, menstrual cycle length, or sperm analysis were observed in sexually mature cynomolgus monkeys that were administered ixekizumab for 13 weeks at a subcutaneous dose of 50 mg/kg/week (19 times the MRHD on a mg/kg basis). The monkeys were not mated to evaluate fertility.</p></div></section>\",\n            \"instructionsForUse\": \"<section class=\\\"Section\\\" data-sectioncode=\\\"59845-8\\\"><a name=\\\"s92\\\"></a><a name=\\\"section-18\\\"></a><p></p><h1>TALTZ 20 mg Prefilled Syringe</h1><table class=\\\"Noautorules\\\" width=\\\"100%\\\"><col align=\\\"left\\\" width=\\\"100.000%\\\"/><tbody class=\\\"Headless\\\"><tr><td align=\\\"center\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">INSTRUCTIONS FOR USE</span></td></tr><tr><td align=\\\"center\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">TALTZ<span class=\\\"Sup\\\">®</span> [tol-t-s]</span><br/><span class=\\\"Bold\\\">(ixekizumab)</span><br/><span class=\\\"Bold\\\">injection, for subcutaneous use</span><br/><span class=\\\"Bold\\\">20 mg/0.25 mL single-dose prefilled syringe</span></td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\">          This Instructions for Use contains information on how to inject TALTZ.                    </td></tr><tr><td align=\\\"center\\\" valign=\\\"top\\\"><br/><a name=\\\"f201\\\"></a><img alt=\\\"Figure\\n\\\" src=\\\"taltz-20mg-pfs-ifu-1.jpg\\\"/></td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\"></td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\"></td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Important Information You Need to  Know Before Giving TALTZ Injection  to Your Child</span></td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\"><ul class=\\\"Disc\\\"><li>Your child's healthcare provider or nurse should show you how to prepare and inject TALTZ using the prefilled syringe. <span class=\\\"Bold\\\">Do not give</span> the TALTZ  prefilled syringe to your child until you have been shown how to inject TALTZ.</li><li>Children ages 6 to 17 years of age should not inject themselves with TALTZ. You or an adult caregiver should prepare and give TALTZ injections to your child.</li><li>You should read this Instructions for Use before injecting TALTZ and each time your child gets a refill. Keep the Instructions for Use and refer to them as needed.</li><li>Each TALTZ prefilled syringe contains 1 dose (20 mg) of TALTZ. <span class=\\\"Bold\\\">The syringe is for one-time use only. Do not</span> share or reuse the TALTZ prefilled syringe. Your child may give or get an infection.</li><li>Your child's healthcare provider may help you decide where on the body to inject the dose. Do not give an injection in an area of the skin that is tender, bruised, red or hard, or in an area of skin that is affected by psoriasis. Read the <span class=\\\"Bold\\\">“<a href=\\\"#p206\\\">Choose the injection site</a>”</span> section of these instructions to help you choose which area can work best.</li></ul></td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\"><ul class=\\\"Disc\\\"><li>If you have vision problems, <span class=\\\"Bold\\\">do not</span> use TALTZ prefilled syringe without help.</li></ul></td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\"></td></tr></tbody></table><table class=\\\"Noautorules\\\" width=\\\"100%\\\"><col align=\\\"left\\\" width=\\\"5.000%\\\"/><col align=\\\"left\\\" width=\\\"47.500%\\\"/><col align=\\\"left\\\" width=\\\"47.500%\\\"/><tbody class=\\\"Headless\\\"><tr><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Before you use the TALTZ prefilled syringe, read and carefully follow all the step-by-step instructions.</span></td></tr><tr><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Parts of the TALTZ prefilled syringe</span></td></tr><tr><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"> </td></tr><tr><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><a name=\\\"f202\\\"></a><img alt=\\\"Figure\\n\\\" src=\\\"taltz-20mg-pfs-ifu-2.jpg\\\"/></td></tr><tr><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"> </td></tr><tr><td align=\\\"left\\\" colspan=\\\"1\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Step 1</span></td><td align=\\\"left\\\" colspan=\\\"2\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Preparing to Inject TALTZ</span></td></tr><tr><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"> </td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Step 1a</span></td><td align=\\\"left\\\" valign=\\\"top\\\"><ul class=\\\"Disc\\\"><li><span class=\\\"Bold\\\">Take the TALTZ prefilled syringe from the refrigerator.</span></li><li>Remove the prefilled syringe from the package. </li><li>Leave the needle cap on the syringe until you are ready to inject.</li><li><span class=\\\"Bold\\\">Wait 30 minutes</span> to let the prefilled syringe warm to room temperature before you use it.</li><li><span class=\\\"Bold\\\">Do not</span> microwave the syringe, run hot water over it, or leave it in direct sunlight.</li><li><span class=\\\"Bold\\\">Do not</span> shake the prefilled syringe.</li></ul></td><td align=\\\"left\\\" valign=\\\"top\\\"><a name=\\\"f203\\\"></a><img alt=\\\"Figure\\n\\\" src=\\\"ifu-30-min-clock.jpg\\\"/></td></tr><tr><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"> </td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Step 1b</span></td><td align=\\\"left\\\" colspan=\\\"2\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Gather the supplies needed for injection:</span><br/><ul class=\\\"Disc\\\"><li>1 alcohol wipe</li><li>1 cotton ball or piece of gauze</li><li>1 sharps disposal container. See <span class=\\\"Bold\\\">“<a href=\\\"#p204\\\">Disposing of TALTZ</a>”</span></li></ul></td></tr><tr><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"> </td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Step 1c</span></td><td align=\\\"center\\\" valign=\\\"top\\\"><a name=\\\"f204\\\"></a><img alt=\\\"Figure\\n\\\" src=\\\"taltz-20mg-pfs-ifu-3.jpg\\\"/></td><td align=\\\"left\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Inspect the syringe.</span> Leave the needle cap on the syringe until you are ready to inject.<br/><ul class=\\\"Disc\\\"><li>Make sure the name <span class=\\\"Bold\\\">TALTZ</span> appears on the label.</li><li>The medicine inside should be clear. Its color may be colorless to slightly yellow.           </li></ul><span class=\\\"Bold\\\">Do not</span> use the prefilled syringe, and dispose of as directed by your child's healthcare provider or pharmacist if:<br/><ul class=\\\"Disc\\\"><li>the expiration date printed on the label has passed (see <span class=\\\"Bold\\\">Figure A</span>).  </li><li>it looks damaged.</li><li>the medicine is frozen.</li><li>the medicine is cloudy, discolored, or has small particles. The medicine should look clear and colorless to slightly yellow.</li></ul></td></tr><tr><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"> </td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Step 1d</span></td><td align=\\\"left\\\" colspan=\\\"2\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Wash your hands with soap and water before you inject TALTZ.</span></td></tr><tr><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"> </td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Step 1e</span></td><td align=\\\"center\\\" valign=\\\"top\\\"><a name=\\\"f205\\\"></a><img alt=\\\"Figure\\n\\\" src=\\\"taltz-inj-sites-2.jpg\\\"/></td><td align=\\\"left\\\" valign=\\\"top\\\"><p class=\\\"First\\\"><a name=\\\"p206\\\"></a><span class=\\\"Bold\\\">Choose the injection site.</span></p><br/>You may inject in the stomach area (abdomen) or in the thigh, or in the back of the arm (see <span class=\\\"Bold\\\">Figure B</span>). <br/><span class=\\\"Bold\\\">Do not</span> give an injection into areas where the skin is tender, bruised, red or hard, or in an area of skin that is affected by psoriasis.<br/><span class=\\\"Bold\\\">Do not</span> inject within 1 inch of the navel (belly button).<br/><span class=\\\"Bold\\\">Change (alternate) injection sites.</span><br/><ul class=\\\"Disc\\\"><li><span class=\\\"Bold\\\">Do not</span> inject in the exact same spot every time. For example, if the last injection was in the left thigh, the next injection should be in the right thigh, the abdomen, or the back of either arm.</li><li>Talk with your child's healthcare provider about where on the body to best inject TALTZ.</li></ul></td></tr><tr><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"> </td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Step 1f</span></td><td align=\\\"left\\\" colspan=\\\"2\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Prepare the skin.</span> Clean the injection site with an alcohol wipe. Let the injection site dry before you inject TALTZ.</td></tr><tr><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"> </td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Step 2</span></td><td align=\\\"left\\\" colspan=\\\"2\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Injecting TALTZ</span></td></tr><tr><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"> </td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\"><br/>Step 2a</span></td><td align=\\\"center\\\" valign=\\\"top\\\"><br/><a name=\\\"f206\\\"></a><img alt=\\\"Figure\\n\\\" src=\\\"taltz-20mg-pfs-ifu-4.jpg\\\"/></td><td align=\\\"left\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\"><br/>Pull the needle cap off and throw it away (see Figure C).</span><br/><ul class=\\\"Disc\\\"><li><span class=\\\"Bold\\\">Do not</span> put the needle cap back on. You could damage the needle or stick yourself by accident.</li><li><span class=\\\"Bold\\\">Do not</span> touch the needle.</li></ul></td></tr><tr><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"> </td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\"><br/>Step 2b</span></td><td align=\\\"center\\\" valign=\\\"top\\\"><br/><a name=\\\"f207\\\"></a><img alt=\\\"Figure\\n\\\" src=\\\"taltz-20-40-pinch.jpg\\\"/></td><td align=\\\"left\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\"><br/>Gently pinch and hold a fold of skin where you will inject (see Figure D).</span></td></tr><tr><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"> </td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\"><br/>Step 2c</span></td><td align=\\\"center\\\" valign=\\\"top\\\"><br/><a name=\\\"f208\\\"></a><img alt=\\\"Figure\\n\\\" src=\\\"taltz-20mg-pfs-ifu-5.jpg\\\"/></td><td align=\\\"left\\\" valign=\\\"top\\\"><p class=\\\"First\\\"><span class=\\\"Bold\\\"><br/>Insert the needle at a 45-degree angle to inject under the skin (subcutaneous injection) (see Figure E).</span> Then gently let go of the skin. Make sure to keep the needle in place.</p><p><a name=\\\"f209\\\"></a><img alt=\\\"Figure\\n\\\" src=\\\"taltz-20mg-pfs-ifu-6.jpg\\\"/><br/><span class=\\\"Bold\\\">Let go of the skin</span> before you push the plunger in (see <span class=\\\"Bold\\\">Figure F</span>).</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"> </td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Step 2d</span></td><td align=\\\"center\\\" valign=\\\"top\\\"><a name=\\\"f210\\\"></a><img alt=\\\"Figure\\n\\\" src=\\\"taltz-20mg-pfs-ifu-7.jpg\\\"/></td><td align=\\\"left\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Push in the plunger.</span><br/><ul class=\\\"Disc\\\"><li>Slowly push on the thumb pad to push the plunger all the way in until all the medicine is injected (see <span class=\\\"Bold\\\">Figure G</span>).</li><li>The gray syringe plunger should be pushed all the way to the needle end of the syringe.</li><li><span class=\\\"Bold\\\">You should see the gray syringe plunger at the bottom of the syringe body when the injection is complete (see Figure H).</span></li><li>Gently remove the needle from the skin.</li><li>Press a cotton ball or gauze over the injection site. <span class=\\\"Bold\\\">Do not</span> rub the injection site, as this may cause bruising. There may be slight bleeding. This is normal.</li></ul><span class=\\\"Bold\\\">Do not</span> put the needle cap back on the prefilled syringe.<br/></td></tr><tr><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"> </td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Step 3</span></td><td align=\\\"left\\\" colspan=\\\"2\\\" valign=\\\"top\\\"><p class=\\\"First\\\"><a name=\\\"p204\\\"></a><span class=\\\"Bold\\\">Disposing of TALTZ</span></p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"> </td></tr><tr><td align=\\\"left\\\" colspan=\\\"2\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\"><br/>Step 3a</span></td><td align=\\\"center\\\" valign=\\\"top\\\"><br/><a name=\\\"f211\\\"></a><img alt=\\\"Figure\\n\\\" src=\\\"taltz-20mg-pfs-ifu-8.jpg\\\"/></td></tr><tr><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><ul class=\\\"Disc\\\"><li>Put the used TALTZ prefilled syringe in an FDA-cleared sharps disposal container right away after use (see <span class=\\\"Bold\\\">Figure I</span>). <span class=\\\"Bold\\\">Do not</span> throw away (dispose of) the TALTZ prefilled syringe in your household trash.</li></ul></td></tr><tr><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><ul class=\\\"Disc\\\"><li>If you do not have an FDA-cleared sharps disposal container, you may use a household container that is:<ul class=\\\"Circle\\\"><li>made of a heavy-duty plastic,</li><li>can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,</li><li>upright and stable during use,</li><li>leak-resistant, and</li><li>properly labeled to warn of hazardous waste inside the container.</li></ul></li></ul></td></tr><tr><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><ul class=\\\"Disc\\\"><li>When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away needles and syringes. For more information about safe sharps disposal, and for specific information about sharps disposal in the state you live in, go to the FDA's website at: http://www.fda.gov/safesharpsdisposal</li></ul></td></tr><tr><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><ul class=\\\"Disc\\\"><li><span class=\\\"Bold\\\">Do not</span> recycle your used sharps disposal container.</li></ul></td></tr><tr><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"> </td></tr><tr><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Commonly asked questions and answers.</span></td></tr><tr><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"> </td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Q.</span></td><td align=\\\"left\\\" colspan=\\\"2\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">What if I see air bubbles in the TALTZ prefilled syringe?</span></td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">A.</span></td><td align=\\\"left\\\" colspan=\\\"2\\\" valign=\\\"top\\\">It is normal to have air bubbles in the prefilled syringe.</td></tr><tr><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"> </td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Q.</span></td><td align=\\\"left\\\" colspan=\\\"2\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">What if there is a drop of liquid on the tip of the needle when I remove the needle cap?</span></td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">A.</span></td><td align=\\\"left\\\" colspan=\\\"2\\\" valign=\\\"top\\\">It is okay to see a drop of liquid on the tip of the needle.</td></tr><tr><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"> </td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Q.</span></td><td align=\\\"left\\\" colspan=\\\"2\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">What if I cannot push in the plunger?</span></td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">A.</span></td><td align=\\\"left\\\" colspan=\\\"2\\\" valign=\\\"top\\\">If the plunger is stuck or damaged:</td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\"></td><td align=\\\"left\\\" colspan=\\\"2\\\" valign=\\\"top\\\"><ul class=\\\"Disc\\\"><li><span class=\\\"Bold\\\">Do not</span> continue to use the syringe</li></ul></td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\"></td><td align=\\\"left\\\" colspan=\\\"2\\\" valign=\\\"top\\\"><ul class=\\\"Disc\\\"><li>Remove the needle from the skin</li></ul></td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\"></td><td align=\\\"left\\\" colspan=\\\"2\\\" valign=\\\"top\\\"><ul class=\\\"Disc\\\"><li>Dispose of the syringe and get a new one</li></ul></td></tr><tr><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"> </td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Q.</span></td><td align=\\\"left\\\" colspan=\\\"2\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">How can I tell if the injection is complete?</span></td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">A.</span></td><td align=\\\"left\\\" colspan=\\\"2\\\" valign=\\\"top\\\">When the injection is complete:</td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\"></td><td align=\\\"left\\\" colspan=\\\"2\\\" valign=\\\"top\\\"><ul class=\\\"Disc\\\"><li>The gray syringe plunger should be pushed all the way to the needle end of the syringe.</li></ul></td></tr><tr><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"> </td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Q.</span></td><td align=\\\"left\\\" colspan=\\\"2\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">What if the syringe is left at room temperature for longer than 30 minutes?</span></td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">A.</span></td><td align=\\\"left\\\" colspan=\\\"2\\\" valign=\\\"top\\\">If needed, the syringe may be left out of the refrigerator at room temperature up to 86°F (30°C) for up to 5 days if protected from light. Throw away TALTZ if not used within the 5-day period at room temperature. See <span class=\\\"Bold\\\">\\\"Storing TALTZ\\\"</span> for more detail. <br/><br/></td></tr><tr><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">If you have more questions about how to use the TALTZ prefilled syringe:</span></td></tr><tr><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><ul class=\\\"Disc\\\"><li>Call your child's healthcare provider</li><li>Call Lilly at 1-800-545-5979 (1-800-Lilly-Rx)</li><li><p class=\\\"First\\\">Visit www.taltz.com        <br/><a name=\\\"f212\\\"></a><img alt=\\\"Figure\\n\\\" src=\\\"taltz-qr-v1.jpg\\\"/></p></li></ul></td></tr><tr><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"> </td></tr><tr><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Storing TALTZ</span></td></tr><tr><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><ul class=\\\"Disc\\\"><li>Protect TALTZ from light.           </li><li>Store TALTZ in the refrigerator between 36°F to 46°F (2°C to 8°C).            <ul class=\\\"Circle\\\"><li> If needed, you may store TALTZ at room temperature up to 86°F (30°C) for up to 5 days in the original carton to protect from light. Once TALTZ has been stored at room temperature, do not return to the refrigerator. Throw away TALTZ if it is not used within 5 days at room temperature.</li><li>Record the date when TALTZ is first removed from the refrigerator in the spaces provided on the carton.</li></ul></li><li>Do not freeze TALTZ. Do not use if TALTZ has been frozen.</li><li>Do not shake TALTZ.</li></ul></td></tr><tr><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Keep TALTZ and all medicines out of the reach of children.</span><br/><br/></td></tr><tr><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Read the Medication Guide for TALTZ inside this box to learn more about the medicine.</span><br/><br/></td></tr><tr><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><p class=\\\"First\\\"><a name=\\\"f213\\\"></a><img alt=\\\"Figure\\n\\\" src=\\\"logo.jpg\\\"/></p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\">         Eli Lilly and Company<br/><br/>         Indianapolis, IN 46285, USA<br/><br/>         US License Number 1891<br/><br/>         TALTZ is a trademark of Eli Lilly and Company.<br/><br/>         Copyright © 2024 Eli Lilly and Company. All rights reserved.<br/><br/> This Instructions for Use has been approved by the U.S. Food and Drug Administration.<br/><br/>         Approved: February 2024<br/><br/>         TAL-0.25ML-PFS-0001-IFU-20240202</td></tr></tbody></table></section>\",\n            \"mechanismOfAction\": \"<section class=\\\"Section\\\" data-sectioncode=\\\"43679-0\\\"><a name=\\\"s55\\\"></a><a name=\\\"section-9.1\\\"></a><p></p><h2>12.1 Mechanism of Action</h2><p class=\\\"First\\\">Ixekizumab is a humanized IgG4 monoclonal antibody that selectively binds with the interleukin 17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor. IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Ixekizumab inhibits the release of proinflammatory cytokines and chemokines.</p></section>\",\n            \"contraindications\": \"<section class=\\\"Section\\\" data-sectioncode=\\\"34070-3\\\"><a name=\\\"s13\\\"></a><a name=\\\"section-4\\\"></a><p></p><h1>4 CONTRAINDICATIONS</h1><p class=\\\"First\\\">TALTZ is contraindicated in patients with a previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients <span class=\\\"Italics\\\">[see Warnings and Precautions (<a href=\\\"#s17\\\">5.3</a>)]</span>.</p></section>\",\n            \"highlights\": {\n                \"dosageAndAdministration\": \"<div><p class=\\\"Highlighta\\\">Administer by subcutaneous injection. </p><p class=\\\"Highlighta\\\">Adult Plaque Psoriasis (<a href=\\\"#s6\\\">2.2</a>) </p><ul class=\\\"Disc\\\"><li>Recommended dosage is 160 mg (two 80 mg injections) at Week 0, followed by 80 mg at Weeks 2, 4, 6, 8, 10, and 12, then 80 mg every 4 weeks.</li></ul><p class=\\\"Highlighta\\\">Pediatric Plaque Psoriasis (<a href=\\\"#s7\\\">2.3</a>) </p><ul class=\\\"Disc\\\"><li>For patients weighing greater than 50 kg, recommended dosage is 160 mg (two 80 mg injections) at Week 0, followed by 80 mg every 4 weeks.</li><li>For patients weighing 25-50 kg, recommended dosage is 80 mg at Week 0, followed by 40 mg every 4 weeks.</li><li>For patients weighing less than 25 kg, recommended dosage is 40 mg at Week 0, followed by 20 mg every 4 weeks.</li></ul><p class=\\\"Highlighta\\\">Psoriatic Arthritis (<a href=\\\"#s8\\\">2.4</a>) </p><ul class=\\\"Disc\\\"><li>Recommended dosage is 160 mg by subcutaneous injection (two 80 mg injections) at Week 0, followed by 80 mg every 4 weeks.</li><li>For psoriatic arthritis patients with coexistent moderate-to-severe plaque psoriasis, use the dosing regimen for adult plaque psoriasis. (<a href=\\\"#s6\\\">2.2</a>)</li><li>TALTZ may be administered alone or in combination with a conventional DMARD (e.g., methotrexate).</li></ul><p class=\\\"Highlighta\\\">Ankylosing Spondylitis (<a href=\\\"#s9\\\">2.5</a>) </p><ul class=\\\"Disc\\\"><li>Recommended dosage is 160 mg by subcutaneous injection (two 80 mg injections) at Week 0, followed by 80 mg every 4 weeks.</li></ul><p class=\\\"Highlighta\\\">Non-radiographic Axial Spondyloarthritis (<a href=\\\"#s9a\\\">2.6</a>) </p><ul class=\\\"Disc\\\"><li>Recommended dosage is 80 mg by subcutaneous injection every 4 weeks.</li></ul></div>\"\n            }\n        }\n    },\n    {\n        \"drugName\": \"Trulicity Demo Pen\",\n        \"setId\": \"463050bd-2b1c-40f5-b3c3-0a04bb433309\",\n        \"slug\": \"trulicity-463050b\",\n        \"labeler\": \"Lilly\",\n        \"label\": {\n            \"boxedWarning\": \"<div class=\\\"Warning\\\"><a name=\\\"s2\\\"></a><a name=\\\"section-1\\\"></a><p></p><h1>WARNING: RISK OF THYROID C-CELL TUMORS</h1><ul class=\\\"Disc\\\"><li><span class=\\\"Bold\\\">In male and female rats, dulaglutide causes a dose-related and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) after lifetime exposure. It is unknown whether TRULICITY causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of dulaglutide-induced rodent thyroid C-cell tumors has not been determined</span><span class=\\\"Bold Italics\\\">[see Warnings and Precautions (<a href=\\\"#s12\\\">5.1</a>), and Nonclinical Toxicology (<a href=\\\"#s74\\\">13.1</a>)]</span><span class=\\\"Bold\\\">.</span></li><li><span class=\\\"Bold\\\">TRULICITY is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC with use of TRULICITY and inform them of symptoms of thyroid tumors (e.g., mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with TRULICITY</span><span class=\\\"Bold Italics\\\">[see Contraindications (<a href=\\\"#s10\\\">4</a>) and Warnings and Precautions (<a href=\\\"#s12\\\">5.1</a>)]</span><span class=\\\"Bold\\\">.</span></li></ul></div>\",\n            \"genericName\": \"Dulaglutide\",\n            \"labelerName\": \"Eli Lilly and Company\",\n            \"productType\": \"HUMAN PRESCRIPTION DRUG LABEL\",\n            \"effectiveTime\": \"20241101\",\n            \"title\": \"Trulicity\",\n            \"indicationsAndUsage\": \"<section class=\\\"Section\\\" data-sectioncode=\\\"34067-9\\\"><a name=\\\"s3\\\"></a><a name=\\\"section-1\\\"></a><p></p><h1>1 INDICATIONS AND USAGE</h1><p class=\\\"First\\\">TRULICITY<span class=\\\"Sup\\\">®</span> is indicated:</p><ul class=\\\"Disc\\\"><li>As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.</li><li>To reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors.</li></ul><p><span class=\\\"Underline\\\">Limitations of Use</span></p><p>TRULICITY:</p><ul class=\\\"Disc\\\"><li>Has not been studied in patients with a history of pancreatitis <span class=\\\"Italics\\\">[see Warnings and Precautions (<a href=\\\"#s13\\\">5.2</a>)]</span>. Consider other antidiabetic therapies in patients with a history of pancreatitis.</li><li>Should not be used in patients with type 1 diabetes mellitus.</li><li>Has not been studied in patients with severe gastrointestinal disease, including severe gastroparesis and is therefore not recommended in these patients <span class=\\\"Italics\\\">[see Warnings and Precautions (<a href=\\\"#s17\\\">5.6</a>)]</span>.</li></ul></section>\",\n            \"dosageAndAdministration\": \"<section class=\\\"Section\\\" data-sectioncode=\\\"34068-7\\\"><a name=\\\"s4\\\"></a><a name=\\\"section-2\\\"></a><p></p><h1>2 DOSAGE AND ADMINISTRATION</h1><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s5\\\"></a><a name=\\\"section-2.1\\\"></a><p></p><h2>2.1 Adult Dosage</h2><ul class=\\\"Disc\\\"><li>The recommended starting dosage of TRULICITY is 0.75 mg injected subcutaneously once weekly. Follow the dosage escalation below to reduce the risk of gastrointestinal adverse reactions <span class=\\\"Italics\\\">[see Warnings and Precautions (<a href=\\\"#s17\\\">5.6</a>) and Adverse Reactions (<a href=\\\"#s22\\\">6.1</a>)].</span></li><li>After 4 weeks, the dosage may be increased to 1.5 mg once weekly for additional glycemic control.</li><li>If additional glycemic control is needed, increase the dosage in 1.5 mg increments after at least 4 weeks on the current dosage.</li><li>The maximum recommended dosage is 4.5 mg injected subcutaneously once weekly.</li></ul></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s6\\\"></a><a name=\\\"section-2.2\\\"></a><p></p><h2>2.2 Pediatric Dosage</h2><ul class=\\\"Disc\\\"><li>The recommended starting dosage of TRULICITY is 0.75 mg injected subcutaneously once weekly.</li><li>If additional glycemic control is needed, increase the dosage to the maximum recommended dosage of 1.5 mg once weekly after at least 4 weeks on the 0.75 mg dosage to reduce the risk of gastrointestinal adverse reactions <span class=\\\"Italics\\\">[see Warnings and Precautions (<a href=\\\"#s17\\\">5.6</a>) and Adverse Reactions (<a href=\\\"#s22\\\">6.1</a>)]</span>.</li></ul></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s7\\\"></a><a name=\\\"section-2.3\\\"></a><p></p><h2>2.3 Recommendations Regarding Missed Dose</h2><ul class=\\\"Disc\\\"><li>If a dose is missed, instruct patients to administer the dose as soon as possible if there are at least 3 days (72 hours) until the next scheduled dose. If less than 3 days remain before the next scheduled dose, skip the missed dose and administer the next dose on the regularly scheduled day. In each case, patients can then resume their regular once weekly dosing schedule.</li><li>The day of weekly administration can be changed, if necessary, as long as the last dose was administered 3 or more days before the new day of administration.</li></ul></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s8\\\"></a><a name=\\\"section-2.4\\\"></a><p></p><h2>2.4 Important Administration Instructions</h2><ul class=\\\"Disc\\\"><li>Prior to initiation, train patients and caregivers on proper injection technique <span class=\\\"Italics\\\">[see Instructions for Use]</span>.</li><li>Administer TRULICITY once weekly, any time of day, with or without food.</li><li>Inject TRULICITY subcutaneously in the abdomen, thigh, or upper arm.</li><li>Rotate injection sites with each dose.</li><li>Inspect TRULICITY visually before use. It should appear clear and colorless. Do not use TRULICITY if particulate matter or coloration is seen.</li><li>When using TRULICITY with insulin, administer as separate injections and never mix. It is acceptable to inject TRULICITY and insulin in the same body region, but the injections should not be adjacent to each other.</li></ul></div></section>\",\n            \"dosageFormsAndStrengths\": \"<section class=\\\"Section\\\" data-sectioncode=\\\"43678-2\\\"><a name=\\\"s9\\\"></a><a name=\\\"section-3\\\"></a><p></p><h1>3 DOSAGE FORMS AND STRENGTHS</h1><p class=\\\"First\\\">Injection: TRULICITY is a clear and colorless solution available as:</p><ul class=\\\"Disc\\\"><li>0.75 mg/0.5 mL solution in a single-dose pen</li><li>1.5 mg/0.5 mL solution in a single-dose pen</li><li>3 mg/0.5 mL solution in a single-dose pen</li><li>4.5 mg/0.5 mL solution in a single-dose pen</li></ul></section>\",\n            \"warningsAndPrecautions\": \"<section class=\\\"Section\\\" data-sectioncode=\\\"43685-7\\\"><a name=\\\"s11\\\"></a><a name=\\\"section-5\\\"></a><p></p><h1>5 WARNINGS AND PRECAUTIONS</h1><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s12\\\"></a><a name=\\\"section-5.1\\\"></a><p></p><h2>5.1 Risk of Thyroid C-cell Tumors</h2><p class=\\\"First\\\">In male and female rats, dulaglutide causes a dose-related and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) after lifetime exposure <span class=\\\"Italics\\\">[see Nonclinical Toxicology (<a href=\\\"#s74\\\">13.1</a>)]</span>. Glucagon-like peptide-1 (GLP-1) receptor agonists have induced thyroid C-cell adenomas and carcinomas in mice and rats at clinically relevant exposures. It is unknown whether TRULICITY will cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of dulaglutide-induced rodent thyroid C-cell tumors has not been determined.</p><p>One case of MTC was reported in a patient treated with TRULICITY in a clinical trial. This patient had pretreatment calcitonin levels approximately 8 times the upper limit of normal (ULN). An additional case of C-cell hyperplasia with elevated calcitonin levels following treatment was reported in the cardiovascular outcomes trial (REWIND). Cases of MTC in patients treated with liraglutide, another GLP-1 receptor agonist, have been reported in the postmarketing period; the data in these reports are insufficient to establish or exclude a causal relationship between MTC and GLP-1 receptor agonist use in humans.</p><p>TRULICITY is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2. Counsel patients regarding the potential risk for MTC with the use of TRULICITY and inform them of symptoms of thyroid tumors (e.g. a mass in the neck, dysphagia, dyspnea, persistent hoarseness).</p><p>Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with TRULICITY. Such monitoring may increase the risk of unnecessary procedures, due to the low test specificity for serum calcitonin and a high background incidence of thyroid disease. Significantly elevated serum calcitonin values may indicate MTC and patients with MTC usually have calcitonin values &gt;50 ng/L. If serum calcitonin is measured and found to be elevated, the patient should be further evaluated. Patients with thyroid nodules noted on physical examination or neck imaging should also be further evaluated.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s13\\\"></a><a name=\\\"section-5.2\\\"></a><p></p><h2>5.2 Pancreatitis</h2><p class=\\\"First\\\">In a pooled analysis from the original registration studies, 12 (3.4 cases per 1000 patient years) pancreatitis-related adverse reactions were reported in patients exposed to TRULICITY versus 3 in non-incretin comparators (2.7 cases per 1000 patient years). An analysis of adjudicated events revealed 5 cases of confirmed pancreatitis in patients exposed to TRULICITY (1.4 cases per 1000 patient years) versus 1 case in non-incretin comparators (0.88 cases per 1000 patient years).</p><p>Based on an analysis of adjudicated events in a clinical trial evaluating Trulicity 1.5 mg, 3 mg, or 4.5 mg once weekly, pancreatitis occurred in 1 patient exposed to TRULICITY 1.5 mg (0.2%), in 2 patients exposed to TRULICITY 3 mg (0.3%), and 3 patients exposed to TRULICITY 4.5 mg (0.5%).</p><p>After initiation of TRULICITY, observe patients carefully for signs and symptoms of pancreatitis, including persistent severe abdominal pain, sometimes radiating to the back, which may or may not be accompanied by vomiting. If pancreatitis is suspected, promptly discontinue TRULICITY and initiate appropriate management. If pancreatitis is confirmed, TRULICITY should not be restarted. TRULICITY has not been evaluated in patients with a prior history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s14\\\"></a><a name=\\\"section-5.3\\\"></a><p></p><h2>5.3 Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin</h2><p class=\\\"First\\\">Patients receiving TRULICITY in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia <span class=\\\"Italics\\\">[see Adverse Reactions (<a href=\\\"#s22\\\">6.1</a>) and Drug Interactions (<a href=\\\"#s37\\\">7</a>)].</span></p><p>The risk of hypoglycemia may be lowered by a reduction in the dose of sulfonylurea (or other concomitantly administered insulin secretagogue) or insulin. Inform patients using these concomitant medications of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s15\\\"></a><a name=\\\"section-5.4\\\"></a><p></p><h2>5.4 Hypersensitivity Reactions</h2><p class=\\\"First\\\">There have been postmarketing reports of serious hypersensitivity reactions including anaphylactic reactions and angioedema in patients treated with TRULICITY <span class=\\\"Italics\\\">[see Adverse Reactions (<a href=\\\"#s36\\\">6.2</a>)]</span>. If a hypersensitivity reaction occurs, discontinue TRULICITY; treat promptly per standard of care, and monitor until signs and symptoms resolve. TRULICITY is contraindicated in patients with a previous serious hypersensitivity reaction to dulaglutide or to any of the components of TRULICITY.</p><p>Anaphylaxis and angioedema have been reported with other GLP-1 receptor agonists. Use caution in a patient with a history of angioedema or anaphylaxis with another GLP-1 receptor agonist because it is unknown whether such patients will be predisposed to anaphylaxis with TRULICITY.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s16\\\"></a><a name=\\\"section-5.5\\\"></a><p></p><h2>5.5 Acute Kidney Injury</h2><p class=\\\"First\\\">In patients treated with GLP-1 receptor agonists, including TRULICITY, there have been postmarketing reports of acute renal failure and worsening of chronic renal failure, which may sometimes require hemodialysis. Some of these events were reported in patients without known underlying renal disease. A majority of reported events occurred in patients who had experienced nausea, vomiting, diarrhea, or dehydration. Because these reactions may worsen renal function, use caution when initiating or escalating doses of TRULICITY in patients with renal impairment. Monitor renal function in patients with renal impairment reporting severe adverse gastrointestinal reactions <span class=\\\"Italics\\\">[see Use in Specific Populations (<a href=\\\"#s51\\\">8.6</a>)]</span>.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s17\\\"></a><a name=\\\"section-5.6\\\"></a><p></p><h2 style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span>5.6 Severe Gastrointestinal Adverse Reactions</h2><p class=\\\"First\\\" style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span>Use of TRULICITY has been associated with gastrointestinal adverse reactions, sometimes severe <span class=\\\"Italics\\\">[see Adverse Reactions (<a href=\\\"#s22\\\">6.1</a>)]</span>. In the pool of placebo-controlled trials, severe gastrointestinal adverse reactions were reported more frequently among patients receiving TRULICITY (0.75 mg 2.2%, 1.5 mg 4.3%) than placebo (1.4%).</p><p style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span>TRULICITY has not been studied in patients with severe gastrointestinal disease, including severe gastroparesis, and is therefore not recommended in these patients.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s18\\\"></a><a name=\\\"section-5.7\\\"></a><p></p><h2>5.7 Diabetic Retinopathy Complications in Patients with a History of Diabetic Retinopathy</h2><p class=\\\"First\\\">In a cardiovascular outcomes trial with a median follow up of 5.4 years involving patients with type 2 diabetes with established cardiovascular disease or multiple cardiovascular risk factors, diabetic retinopathy complications occurred in patients treated with TRULICITY 1.5 mg (1.9%) and placebo (1.5%). These events were prospectively ascertained as a secondary composite endpoint. The proportion of patients with diabetic retinopathy complications was larger among patients with a history of diabetic retinopathy at baseline (TRULICITY 8.5%, placebo 6.2%) than among patients without a known history of diabetic retinopathy (TRULICITY 1%, placebo 1%).</p><p>Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s19\\\"></a><a name=\\\"section-5.8\\\"></a><p></p><h2>5.8 Acute Gallbladder Disease</h2><p class=\\\"First\\\">Acute events of gallbladder disease such as cholelithiasis or cholecystitis have been reported in GLP-1 receptor agonist trials and postmarketing. In a cardiovascular outcomes trial with a median follow up of 5.4 years, cholelithiasis occurred at a rate of 0.62/100 patient-years in TRULICITY-treated patients and 0.56/100 patient-years in placebo-treated patients after adjusting for prior cholecystectomy. Serious events of acute cholecystitis were reported in 0.5% and 0.3% of patients on TRULICITY and placebo respectively. If cholelithiasis is suspected, gallbladder studies and appropriate clinical follow-up are indicated.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s20\\\"></a><a name=\\\"section-5.9\\\"></a><p></p><h2 style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span>5.9 Pulmonary Aspiration During General Anesthesia or Deep Sedation</h2><p class=\\\"First\\\" style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span>TRULICITY delays gastric emptying <span class=\\\"Italics\\\">[see Clinical Pharmacology (<a href=\\\"#s58\\\">12.2</a>)]</span>. There have been rare postmarketing reports of pulmonary aspiration in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation who had residual gastric contents despite reported adherence to preoperative fasting recommendations.</p><p style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span>Available data are insufficient to inform recommendations to mitigate the risk of pulmonary Aspiration During General anesthesia or deep sedation in patients taking TRULICITY, including whether modifying preoperative fasting recommendations or temporarily discontinuing TRULICITY could reduce the incidence of retained gastric contents. Instruct patients to inform healthcare providers prior to any planned surgeries or procedures if they are taking TRULICITY.</p></div></section>\",\n            \"adverseReactions\": \"<section class=\\\"Section\\\" data-sectioncode=\\\"34084-4\\\"><a name=\\\"s21\\\"></a><a name=\\\"section-6\\\"></a><p></p><h1>6 ADVERSE REACTIONS</h1><p class=\\\"First\\\">The following serious reactions are described below or elsewhere in the prescribing information:</p><ul class=\\\"Disc\\\"><li>Risk of Thyroid C-cell Tumors <span class=\\\"Italics\\\">[see Warnings and Precautions (<a href=\\\"#s12\\\">5.1</a>)]</span></li><li>Pancreatitis <span class=\\\"Italics\\\">[see Warnings and Precautions (<a href=\\\"#s13\\\">5.2</a>)]</span></li><li>Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin <span class=\\\"Italics\\\">[see Warnings and Precautions (<a href=\\\"#s14\\\">5.3</a>)]</span></li><li>Hypersensitivity Reactions <span class=\\\"Italics\\\">[see Warnings and Precautions (<a href=\\\"#s15\\\">5.4</a>)]</span></li><li>Acute Kidney Injury <span class=\\\"Italics\\\">[see Warnings and Precautions (<a href=\\\"#s16\\\">5.5</a>)]</span></li><li>Severe Gastrointestinal Adverse Reactions <span class=\\\"Italics\\\">[see Warnings and Precautions (<a href=\\\"#s17\\\">5.6</a>)]</span></li><li>Diabetic Retinopathy Complications in Patients with a History of Diabetic Retinopathy <span class=\\\"Italics\\\">[see Warnings and Precautions (<a href=\\\"#s18\\\">5.7</a>)]</span></li><li>Acute Gallbladder Disease <span class=\\\"Italics\\\">[see Warnings and Precautions (<a href=\\\"#s19\\\">5.8</a>)]</span></li><li>Pulmonary Aspiration During General Anesthesia or Deep Sedation <span class=\\\"Italics\\\">[see Warnings and Precautions (<a href=\\\"#s20\\\">5.9</a>)]</span></li></ul><div class=\\\"Section\\\" data-sectioncode=\\\"90374-0\\\"><a name=\\\"s22\\\"></a><a name=\\\"section-6.1\\\"></a><p></p><h2>6.1 Clinical Trials Experience</h2><p class=\\\"First\\\">Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.</p><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s23\\\"></a><a name=\\\"section-6.1.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Bold\\\">Adverse Reactions in the Clinical Trials in Adults with Type 2 Diabetes Mellitus</span></p><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s24\\\"></a><a name=\\\"section-6.1.1.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Pool of Adult Placebo-Controlled Trials for TRULICITY 0.75 mg and 1.5 mg Doses</span></p><p>The data in <a href=\\\"#t1\\\">Table 1</a> are derived from a pool of placebo-controlled trials and include 1,670 adult patients with type 2 diabetes mellitus exposed to TRULICITY with a mean duration of exposure of 23.8 weeks <span class=\\\"Italics\\\">[see Clinical Studies (<a href=\\\"#s76\\\">14</a>)]</span>. The mean age of patients was 56 years, 1% were 75 years or older and 53% were male. The population was 69% White, 7% Black or African American, 13% Asian; 30% were of Hispanic or Latino ethnicity. At baseline, the population had diabetes for an average of 8 years, a mean HbA1c of 8.0%, and 2.5% of the population reported retinopathy. Baseline estimated renal function was normal or mildly impaired (eGFR ≥60 mL/min/1.73 m<span class=\\\"Sup\\\">2</span>) in 96%.</p><p><a href=\\\"#t1\\\">Table 1</a> shows adverse reactions, excluding hypoglycemia, occurring in ≥5% of TRULICITY treated adult patients and more commonly than placebo in a pool of placebo-controlled trials.</p><a name=\\\"t1\\\"></a><table width=\\\"100%\\\"><caption><span>Table 1: Adverse Reactions in Pool of Placebo-Controlled Trials That Occurred in ≥5% of TRULICITY-Treated Adult Patients with Type 2 Diabetes Mellitus</span></caption><col align=\\\"left\\\" width=\\\"25.000%\\\"/><col align=\\\"left\\\" width=\\\"25.000%\\\"/><col align=\\\"left\\\" width=\\\"25.000%\\\"/><col align=\\\"left\\\" width=\\\"25.000%\\\"/><tfoot><tr class=\\\"First\\\"><td align=\\\"left\\\" colspan=\\\"4\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">a</span> Includes diarrhea, fecal volume increased, frequent bowel movements.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"4\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">b</span> Includes retching, vomiting, vomiting projectile.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"4\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">c</span> Includes abdominal discomfort, abdominal pain, abdominal pain lower, abdominal pain upper, abdominal tenderness, gastrointestinal pain.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"4\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">d</span> Includes fatigue, asthenia, malaise.</p></td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" colspan=\\\"4\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"> Note: Percentages reflect the number of patients that reported at least 1 treatment-emergent occurrence of the adverse reaction.</p></td></tr></tfoot><tbody class=\\\"Headless\\\"><tr class=\\\"First\\\"><td align=\\\"center\\\" class=\\\"Botrule Lrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Adverse Reaction</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Placebo</span><br/><span class=\\\"Bold\\\">(N=568)</span><br/><span class=\\\"Bold\\\">%</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">TRULICITY 0.75 mg</span><br/><span class=\\\"Bold\\\">(N=836)</span><br/><span class=\\\"Bold\\\">%</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">TRULICITY 1.5 mg</span><br/><span class=\\\"Bold\\\">(N=834)</span><br/><span class=\\\"Bold\\\">%</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Nausea</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">5.3</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">12.4</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">21.1</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Diarrhea<span class=\\\"Sup\\\">a</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">6.7</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">8.9</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">12.6</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Vomiting<span class=\\\"Sup\\\">b</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">2.3</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">6.0</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">12.7</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Abdominal Pain<span class=\\\"Sup\\\">c</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">4.9</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">6.5</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">9.4</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Decreased Appetite</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">1.6</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">4.9</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">8.6</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Dyspepsia</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">2.3</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">4.1</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">5.8</td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Fatigue<span class=\\\"Sup\\\">d</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">2.6</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">4.2</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">5.6</td></tr></tbody></table><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s25\\\"></a><a name=\\\"section-6.1.1.1.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Gastrointestinal Adverse Reactions</span></p><p>In the pool of placebo-controlled trials, gastrointestinal (GI) adverse reactions occurred more frequently among patients who received TRULICITY compared to patients who received placebo (placebo 21%, 0.75 mg 32%, 1.5 mg 41%). A higher percentage of patients who received TRULICITY 0.75 mg (1.3%) and TRULICITY 1.5 mg (3.5%) discontinued treatment due to GI adverse reactions than patients who received placebo (0.2%). Investigators graded the severity of GI adverse reactions that occurred in those treated with 0.75 mg and 1.5 mg of TRULICITY as “mild” in 58% and 48% of cases, respectively, “moderate” in 35% and 42% of cases, respectively, or “severe” in 7% and 11% of cases, respectively.</p><p>The following GI adverse reactions were reported more frequently in TRULICITY-treated patients than placebo -treated patients (frequencies listed, respectively, as: placebo; 0.75 mg; 1.5 mg): constipation (0.7%, 3.9%, 3.7%), flatulence (1.4%, 1.4%, 3.4%), abdominal distension (0.7%, 2.9%, 2.3%), gastroesophageal reflux disease (0.5%, 1.7%, 2.0%), and eructation (0.2%, 0.6%, 1.6%).</p></div></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s26\\\"></a><a name=\\\"section-6.1.1.2\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Adult Dose Ranging Trial for TRULICITY 3 mg and 4.5 mg Doses</span></p><p><a href=\\\"#t2\\\">Table 2</a> shows adverse reactions occurring ≥5% in any of the treatment groups through 36 weeks in a clinical trial with 1842 adult patients with type 2 diabetes mellitus treated with TRULICITY 1.5 mg, 3 mg, or 4.5 mg subcutaneously once weekly as an add-on to metformin <span class=\\\"Italics\\\">[see Clinical Studies (<a href=\\\"#s79\\\">14.3</a>)]</span>. The adverse reaction profile is consistent with previous clinical trials in adults.</p><a name=\\\"t2\\\"></a><table width=\\\"100%\\\"><caption><span>Table 2: Adverse Reactions That Occurred in ≥5% of TRULICITY-treated Adult Patients with Type 2 Diabetes Mellitus in a Clinical Trial through 36 Weeks<span class=\\\"Sup\\\">a</span></span></caption><col align=\\\"left\\\" width=\\\"25.000%\\\"/><col align=\\\"left\\\" width=\\\"25.000%\\\"/><col align=\\\"left\\\" width=\\\"25.000%\\\"/><col align=\\\"left\\\" width=\\\"25.000%\\\"/><tfoot><tr class=\\\"First Last\\\"><td align=\\\"left\\\" colspan=\\\"4\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">a</span> Percentages reflect the number of patients that reported at least 1 treatment-emergent occurrence of the adverse reaction.</p></td></tr></tfoot><tbody class=\\\"Headless\\\"><tr class=\\\"First\\\"><td align=\\\"center\\\" class=\\\"Botrule Lrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Adverse Reaction</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">TRULICITY 1.5 mg</span><br/><span class=\\\"Bold\\\">(N=612)</span><br/><span class=\\\"Bold\\\">%</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">TRULICITY 3 mg</span><br/><span class=\\\"Bold\\\">(N=616)</span><br/><span class=\\\"Bold\\\">%</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">TRULICITY 4.5 mg</span><br/><span class=\\\"Bold\\\">(N=614)</span><br/><span class=\\\"Bold\\\">%</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Nausea</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">13.4</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">15.6</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">16.4</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Diarrhea</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">7.0</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">11.4</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">10.7</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Vomiting</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">5.6</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">8.3</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">9.3</td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Dyspepsia</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">2.8</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">5.0</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">2.6</td></tr></tbody></table></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s27\\\"></a><a name=\\\"section-6.1.1.3\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Other Adverse Reactions in Adults</span></p><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s28\\\"></a><a name=\\\"section-6.1.1.3.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Hypoglycemia</span></p><p><a href=\\\"#t3\\\">Table 3</a> summarizes the incidence of hypoglycemia in the placebo-controlled clinical studies in adult patients with type 2 diabetes mellitus: episodes with a glucose level &lt;54 mg/dL with or without symptoms, and severe hypoglycemia, defined as an episode requiring the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions.</p><a name=\\\"t3\\\"></a><table width=\\\"100%\\\"><caption><span>Table 3: Incidence (%) of Hypoglycemia in Adult Patients with Type 2 Diabetes Mellitus in Placebo-Controlled Trials</span></caption><col align=\\\"left\\\" width=\\\"26.068%\\\"/><col align=\\\"left\\\" width=\\\"24.644%\\\"/><col align=\\\"left\\\" width=\\\"24.644%\\\"/><col align=\\\"left\\\" width=\\\"24.644%\\\"/><tbody class=\\\"Headless\\\"><tr class=\\\"First\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule Toprule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Placebo</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">TRULICITY 0.75 mg</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">TRULICITY 1.5 mg</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"4\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Add-on to Metformin</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">      <span class=\\\"Bold\\\">(26 weeks)</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">N=177</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">N=302</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">N=304</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">     Hypoglycemia with a glucose level &lt;54 mg/dL</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">0</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">0.3</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">0.7</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">     Severe hypoglycemia</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">0</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">0</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">0</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"4\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Add-on to Metformin + Pioglitazone</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">      <span class=\\\"Bold\\\">(26 weeks)</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">N=141</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">N=280</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">N=279</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">     Hypoglycemia with a glucose level &lt;54 mg/dL</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">1.4</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">2.1</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">0</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">     Severe hypoglycemia</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">0</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">0</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">0</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"4\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Add-on to Glimepiride</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">      <span class=\\\"Bold\\\">(24 weeks)</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">N=60</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">-</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">N=239</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">     Hypoglycemia with a glucose level &lt;54 mg/dL</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">0</td><td"